Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series
Chronic actinic dermatitis (CAD) is a rare chronic immunological photo-dermatosis resulting in pruritic eczematous eruption on sun-exposed skin to ultraviolet (UV) light. The disease mechanism may include a delay-type hypersensitivity reaction to an endogenous photo-induced antigen, postulated to be...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.803692/full |
| _version_ | 1819279256876744704 |
|---|---|
| author | Kamran Ali Liming Wu HaiYue Lou Jianbo Zhong YunMi Qiu JiaYang Da JingPeng Shan KaiNing Lu |
| author_facet | Kamran Ali Liming Wu HaiYue Lou Jianbo Zhong YunMi Qiu JiaYang Da JingPeng Shan KaiNing Lu |
| author_sort | Kamran Ali |
| collection | DOAJ |
| description | Chronic actinic dermatitis (CAD) is a rare chronic immunological photo-dermatosis resulting in pruritic eczematous eruption on sun-exposed skin to ultraviolet (UV) light. The disease mechanism may include a delay-type hypersensitivity reaction to an endogenous photo-induced antigen, postulated to be UVR-altered DNA, but the exact pathophysiology is unknown. Minimum erythema dosing and patch testing are diagnostic tools of CAD. There are limited safe and effective treatment options for CAD. Herein, a case series of three patients with severe recalcitrant CAD is presented after being treated with dupilumab off-label. The patients in this study had persistent severe disease and taken the first-line management plan, which consists of topical calcineurin inhibitors (TCI), topical corticosteroids (TCS), and strict photoprotection. However, the above treatment options were not able to control the symptoms. The patients were treated with dupilumab 600 mg first dose, 300 mg biweekly subcutaneously (SC), and hydroxychloroquine. Dupilumab showed excellent clinical benefits, including safe and well-tolerated in chronic actinic dermatitis. Further studies are required to be carried out before being applied in clinical practice. |
| first_indexed | 2024-12-24T00:25:01Z |
| format | Article |
| id | doaj.art-6d2f405a82e54f2da26a29cb37c482f9 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-24T00:25:01Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-6d2f405a82e54f2da26a29cb37c482f92022-12-21T17:24:29ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-02-01910.3389/fmed.2022.803692803692Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case SeriesKamran Ali0Liming Wu1HaiYue Lou2Jianbo Zhong3YunMi Qiu4JiaYang Da5JingPeng Shan6KaiNing Lu7Department of Dermatology, International Education College of Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Oncological Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Oncological Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaChronic actinic dermatitis (CAD) is a rare chronic immunological photo-dermatosis resulting in pruritic eczematous eruption on sun-exposed skin to ultraviolet (UV) light. The disease mechanism may include a delay-type hypersensitivity reaction to an endogenous photo-induced antigen, postulated to be UVR-altered DNA, but the exact pathophysiology is unknown. Minimum erythema dosing and patch testing are diagnostic tools of CAD. There are limited safe and effective treatment options for CAD. Herein, a case series of three patients with severe recalcitrant CAD is presented after being treated with dupilumab off-label. The patients in this study had persistent severe disease and taken the first-line management plan, which consists of topical calcineurin inhibitors (TCI), topical corticosteroids (TCS), and strict photoprotection. However, the above treatment options were not able to control the symptoms. The patients were treated with dupilumab 600 mg first dose, 300 mg biweekly subcutaneously (SC), and hydroxychloroquine. Dupilumab showed excellent clinical benefits, including safe and well-tolerated in chronic actinic dermatitis. Further studies are required to be carried out before being applied in clinical practice.https://www.frontiersin.org/articles/10.3389/fmed.2022.803692/fullchronic actinic dermatitisdupilumabphoto-dermatoseshydroxychloroquinephotodermatitis |
| spellingShingle | Kamran Ali Liming Wu HaiYue Lou Jianbo Zhong YunMi Qiu JiaYang Da JingPeng Shan KaiNing Lu Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series Frontiers in Medicine chronic actinic dermatitis dupilumab photo-dermatoses hydroxychloroquine photodermatitis |
| title | Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series |
| title_full | Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series |
| title_fullStr | Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series |
| title_full_unstemmed | Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series |
| title_short | Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series |
| title_sort | clearance of chronic actinic dermatitis with dupilumab therapy in chinese patients a case series |
| topic | chronic actinic dermatitis dupilumab photo-dermatoses hydroxychloroquine photodermatitis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.803692/full |
| work_keys_str_mv | AT kamranali clearanceofchronicactinicdermatitiswithdupilumabtherapyinchinesepatientsacaseseries AT limingwu clearanceofchronicactinicdermatitiswithdupilumabtherapyinchinesepatientsacaseseries AT haiyuelou clearanceofchronicactinicdermatitiswithdupilumabtherapyinchinesepatientsacaseseries AT jianbozhong clearanceofchronicactinicdermatitiswithdupilumabtherapyinchinesepatientsacaseseries AT yunmiqiu clearanceofchronicactinicdermatitiswithdupilumabtherapyinchinesepatientsacaseseries AT jiayangda clearanceofchronicactinicdermatitiswithdupilumabtherapyinchinesepatientsacaseseries AT jingpengshan clearanceofchronicactinicdermatitiswithdupilumabtherapyinchinesepatientsacaseseries AT kaininglu clearanceofchronicactinicdermatitiswithdupilumabtherapyinchinesepatientsacaseseries |